A Phase 4 interventional study of pregabalin (Lyrica) in Healthy Lactating Women, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a pharmacokinetic study to determine the safety and tolerability of pregabalin in healthy lactating women. The objectives are to determine whether pregabalin is secreted in breast milk and if so, to characterize pregabalin pharmacokinetics in breast milk. Other objectives are to estimate potential infant exposure to pregabalin if administered to lactating women and to characterize the safety and tolerability of pregabalin in lactating women.
Post approval commitment for the FDA
1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.
This study's enrollment of 10 is below the median of 100 across 845 interventional studies indexed under Breast Feeding.
Browse Breast Feeding studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin (Lyrica)
Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
Area under the plasma concentration-time profile from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Maximum Observed Plasma Concentration (Cmax)
Cmax was the peak concentration in plasma post Day 3 dose.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax was the time to peak concentration in plasma post Day 3 dose.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Plasma Half-Life (t1/2)
Plasma decay half-life (t1/2) was the time for the plasma concentration to decrease by one-half. The t1/2 is based on the terminal elimination phase time points from this timeframe.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Average Plasma Concentration During the Dosing Interval (Cav)
Average plasma concentration during the dosing interval (Cav) was calculated by dividing AUCtau (plasma) with tau, where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Minimum Observed Plasma Trough Concentration (Cmin)
Cmin was the minimum observed plasma concentration of a drug after post Day 3 dose.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Apparent Oral Clearance (CL/F)
Apparent oral clearance (CL/F) was calculated by dividing dose by the AUCtau, where tau was the dosing interval of 12 hours. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Area Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk])
AUCtau (breast milk) was the area under the curve for breast milk, from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Maximum Observed Concentration in Breast Milk (Cmax [Breast Milk])
Cmax (breast milk) was the maximum observed concentration in breast milk post Day 3 dose.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Time to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk])
Tmax (breast milk) was time of the maximum observed breast milk concentration Day 3 post-dose.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Terminal Half-Life for Breast Milk (t1/2 [Breast Milk])
The terminal half-life for breast milk (t1/2 \[breast milk\]) was the time measured for breast milk concentration to decrease by one-half. For the first 5 participants enrolled under protocol amendment dated: 18 Sep 2012, breast milk was collected up to 24 hours after Day 3 dosing over the following time intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 hours. Terminal half-life was determined over those points characterizing the elimination phase. For the remaining 5 participants, there were 3 additional collection intervals (24 to 32, 32 to 40, 40 to 48 hours) for characterizing the terminal elimination phase. The t1/2 (breast milk) is based on the terminal elimination phase time points from this timeframe.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Average Breast Milk Concentration During the Dosing Interval (Cav)
Average breast milk concentration during the dosing interval (Cav) was calculated by dividing AUCtau (breast milk) with tau, where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Amount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm)
Aetaubm was the amount excreted in breast milk over the dosing interval tau (12 hours). It was calculated as the sum of (breast milk concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Sample volume was based on ratio of volume weight and density.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Percentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent)
Percentage of dose excreted in breast milk during the dosing interval tau (Aetaubm percent) was calculated by using the formula: 100\*(Aetaubm \[sum of {breast milk concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by dose), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Breast Milk Clearance (CLbm)
Breast milk clearance (CLbm) was calculated by dividing Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) by plasma AUCtau, where tau was the dosing interval of 12 hours.
Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Amount Recovered in Urine During the Dosing Interval Tau (Aetauurine)
Aetauurine was the amount excreted in urine over the dosing interval tau (12 hours). It was calculated as the sum of (urine concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Here, sample volume was based on the ratio of volume weight and density.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Percent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent)
Percent of dose recovered in urine during the dosing interval tau (Aetauurine percent) was calculated as 100\* (Aetau \[sum of {urine concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by the dose), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Renal Clearance (CLr)
Renal clearance (CLr) was the volume of plasma from which the drug was completely removed by the kidney in a given amount of time. It was calculated by dividing Aetauurine (sum of \[urine concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) with the plasma AUCtau, where tau was the dosing interval of 12 hours.
Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Urine: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8 and 8 to 12 hours post-dose on Day 3
Daily Amount of Pregabalin Excreted in Breast Milk (Ae24bm)
Ae24bm was the daily amount of pregabalin excreted in breast milk. It was calculated by the formula: 2 \* Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Milk to Plasma Ratio for AUCtau (MPAUCtau)
MPAUCtau was the ratio of AUCtau (breast milk) to AUCtau (plasma), where tau was the dosing interval of 12 hours.
Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Milk to Plasma Ratio for Maximum Observed Concentration (MPCmax)
Milk to plasma ratio for maximum observed concentration (MPCmax) was calculated as the ratio of Cmax (breast milk) to Cmax (plasma).
Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Body Weight Normalized Infant Dose (BWNID)
Body weight normalized infant dose (BWNID) of pregabalin was the dose that an infant received from breast-feeding and was calculated from the milk to plasma AUCtau ratio multiplied by the average maternal plasma pregabalin concentration (Cav) multiplied by the standardized milk consumption for an infant (150 milliliter/kilogram/day \[mL/kg/day\]), where tau was the dosing interval of 12 hours.
Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Body Weight Normalized Maternal Dose (BWNMD)
Body weight normalized maternal dose (BWNMD) was calculated as the maternal dose in microgram per day (mcg/day) divided by maternal weight in kilogram (kg) at screening.
Time frame: Pre-dose to 24 hours post-dose on Day 3
Infant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM)
Infant dose expressed as percentage of body weight normalized maternal dose (BWNIDPCM) was the relative infant dose (relative to maternal dose) calculated by the formula: 100 \* BWNID (Body Weight Normalized Infant Dose) / Body Weight Normalized Maternal Dose (BWNMD), where tau was the dosing interval of 12 hours.
Time frame: Pre-dose to 24 hours post-dose on Day 3
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
Time frame: Baseline up to 28 days after last dose of study drug
Number of Participants With Laboratory Abnormalities
The following parameters were analyzed for laboratory abnormalities: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume \[MCV\], mean corpuscular hemoglobin \[MCH\], mean corpuscular hemoglobin concentration \[MCHC\], platelets, white blood cell count, lymphocytes, total neutrophils, basophils, eosinophils, monocytes); liver function (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, albumin); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (urine pH, glucose, ketones, protein, urine blood/hemoglobin, nitrite).
Time frame: Baseline up to 28 days after last dose of study drug
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
The following parameters were analyzed for examination of vital signs: electrocardiogram (ECG), systolic and diastolic blood pressure, temperature, pulse rate, respiratory rate, radial pulse and body temperature.
Time frame: Baseline up to 28 days after last dose of study drug
Eligible participants were healthy, lactating females between the ages of 18 and 45 years (inclusive) who were actively breastfeeding or expressing breast milk, who were at least 12 weeks post-partum and not currently pregnant.
| Milestone | Pregabalin |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Area under the plasma concentration-time profile from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.
| microgram*hour/milliliter (mcg*hr/mL) | Pregabalin |
|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | 32.50 ± 24 |
Cmax was the peak concentration in plasma post Day 3 dose.
| mcg/mL | Pregabalin |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 4.67 ± 18 |
Tmax was the time to peak concentration in plasma post Day 3 dose.
| hr | Pregabalin |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 2.01 (1.00 to 3.00) |
Plasma decay half-life (t1/2) was the time for the plasma concentration to decrease by one-half. The t1/2 is based on the terminal elimination phase time points from this timeframe.
| hr | Pregabalin |
|---|---|
| Plasma Half-Life (t1/2) | 5.624 ± 0.65656 |
Average plasma concentration during the dosing interval (Cav) was calculated by dividing AUCtau (plasma) with tau, where tau was the dosing interval of 12 hours.
| mcg/mL | Pregabalin |
|---|---|
| Average Plasma Concentration During the Dosing Interval (Cav) | 2.709 ± 24 |
Cmin was the minimum observed plasma concentration of a drug after post Day 3 dose.
| mcg/mL | Pregabalin |
|---|---|
| Minimum Observed Plasma Trough Concentration (Cmin) | 1.246 ± 36 |
Apparent oral clearance (CL/F) was calculated by dividing dose by the AUCtau, where tau was the dosing interval of 12 hours. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| mL/minute | Pregabalin |
|---|---|
| Apparent Oral Clearance (CL/F) | 76.90 ± 24 |
AUCtau (breast milk) was the area under the curve for breast milk, from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.
| mcg*hr/mL | Pregabalin |
|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk]) | 24.64 ± 27 |
Cmax (breast milk) was the maximum observed concentration in breast milk post Day 3 dose.
| mcg/mL | Pregabalin |
|---|---|
| Maximum Observed Concentration in Breast Milk (Cmax [Breast Milk]) | 2.474 ± 30 |
Tmax (breast milk) was time of the maximum observed breast milk concentration Day 3 post-dose.
| hr | Pregabalin |
|---|---|
| Time to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk]) | 4.63 (3.08 to 6.16) |
The terminal half-life for breast milk (t1/2 \[breast milk\]) was the time measured for breast milk concentration to decrease by one-half. For the first 5 participants enrolled under protocol amendment dated: 18 Sep 2012, breast milk was collected up to 24 hours after Day 3 dosing over the following time intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 hours. Terminal half-life was determined over those points characterizing the elimination phase. For the remaining 5 participants, there were 3 additional collection intervals (24 to 32, 32 to 40, 40 to 48 hours) for characterizing the terminal elimination phase. The t1/2 (breast milk) is based on the terminal elimination phase time points from this timeframe.
| hr | Pregabalin |
|---|---|
| Terminal Half-Life for Breast Milk (t1/2 [Breast Milk]) | 8.117 ± 3.0871 |
Average breast milk concentration during the dosing interval (Cav) was calculated by dividing AUCtau (breast milk) with tau, where tau was the dosing interval of 12 hours.
| mcg/mL | Pregabalin |
|---|---|
| Average Breast Milk Concentration During the Dosing Interval (Cav) | 2.116 ± 27 |
Aetaubm was the amount excreted in breast milk over the dosing interval tau (12 hours). It was calculated as the sum of (breast milk concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Sample volume was based on ratio of volume weight and density.
| mcg | Pregabalin |
|---|---|
| Amount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm) | 286.9 ± 60 |
Percentage of dose excreted in breast milk during the dosing interval tau (Aetaubm percent) was calculated by using the formula: 100\*(Aetaubm \[sum of {breast milk concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by dose), where tau was the dosing interval of 12 hours.
| percentage of dose | Pregabalin |
|---|---|
| Percentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent) | 0.1913 ± 60 |
Breast milk clearance (CLbm) was calculated by dividing Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) by plasma AUCtau, where tau was the dosing interval of 12 hours.
| mL/min | Pregabalin |
|---|---|
| Breast Milk Clearance (CLbm) | 0.1473 ± 60 |
Aetauurine was the amount excreted in urine over the dosing interval tau (12 hours). It was calculated as the sum of (urine concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Here, sample volume was based on the ratio of volume weight and density.
| mg | Pregabalin |
|---|---|
| Amount Recovered in Urine During the Dosing Interval Tau (Aetauurine) | 133.1 ± 12 |
Percent of dose recovered in urine during the dosing interval tau (Aetauurine percent) was calculated as 100\* (Aetau \[sum of {urine concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by the dose), where tau was the dosing interval of 12 hours.
| percentage of dose | Pregabalin |
|---|---|
| Percent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent) | 88.6 ± 12 |
Renal clearance (CLr) was the volume of plasma from which the drug was completely removed by the kidney in a given amount of time. It was calculated by dividing Aetauurine (sum of \[urine concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) with the plasma AUCtau, where tau was the dosing interval of 12 hours.
| mL/min | Pregabalin |
|---|---|
| Renal Clearance (CLr) | 68.16 ± 24 |
Ae24bm was the daily amount of pregabalin excreted in breast milk. It was calculated by the formula: 2 \* Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose), where tau was the dosing interval of 12 hours.
| mcg | Pregabalin |
|---|---|
| Daily Amount of Pregabalin Excreted in Breast Milk (Ae24bm) | 664.6 ± 60 |
MPAUCtau was the ratio of AUCtau (breast milk) to AUCtau (plasma), where tau was the dosing interval of 12 hours.
| ratio | Pregabalin |
|---|---|
| Milk to Plasma Ratio for AUCtau (MPAUCtau) | 0.769 (0.493 to 0.956) |
Milk to plasma ratio for maximum observed concentration (MPCmax) was calculated as the ratio of Cmax (breast milk) to Cmax (plasma).
| ratio | Pregabalin |
|---|---|
| Milk to Plasma Ratio for Maximum Observed Concentration (MPCmax) | 0.5413 (0.335 to 0.755) |
Body weight normalized infant dose (BWNID) of pregabalin was the dose that an infant received from breast-feeding and was calculated from the milk to plasma AUCtau ratio multiplied by the average maternal plasma pregabalin concentration (Cav) multiplied by the standardized milk consumption for an infant (150 milliliter/kilogram/day \[mL/kg/day\]), where tau was the dosing interval of 12 hours.
| mcg/kg/day | Pregabalin |
|---|---|
| Body Weight Normalized Infant Dose (BWNID) | 317.3 ± 27 |
Body weight normalized maternal dose (BWNMD) was calculated as the maternal dose in microgram per day (mcg/day) divided by maternal weight in kilogram (kg) at screening.
| mcg/kg/day | Pregabalin |
|---|---|
| Body Weight Normalized Maternal Dose (BWNMD) | 4343.6 ± 27 |
Infant dose expressed as percentage of body weight normalized maternal dose (BWNIDPCM) was the relative infant dose (relative to maternal dose) calculated by the formula: 100 \* BWNID (Body Weight Normalized Infant Dose) / Body Weight Normalized Maternal Dose (BWNMD), where tau was the dosing interval of 12 hours.
| percentage of dose | Pregabalin |
|---|---|
| Infant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM) | 7.341 ± 27 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.
| participants | Pregabalin |
|---|---|
| Number of Participants with AEs | 8 |
| Number of Participants with SAEs | 0 |
The following parameters were analyzed for laboratory abnormalities: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume \[MCV\], mean corpuscular hemoglobin \[MCH\], mean corpuscular hemoglobin concentration \[MCHC\], platelets, white blood cell count, lymphocytes, total neutrophils, basophils, eosinophils, monocytes); liver function (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, albumin); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (urine pH, glucose, ketones, protein, urine blood/hemoglobin, nitrite).
| participants | Pregabalin |
|---|---|
| Number of Participants With Laboratory Abnormalities | 4 |
The following parameters were analyzed for examination of vital signs: electrocardiogram (ECG), systolic and diastolic blood pressure, temperature, pulse rate, respiratory rate, radial pulse and body temperature.
| participants | Pregabalin |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 |
Collected over Baseline up to 28 days after last dose of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/10 (0%) | 8/10 (80%) |
| Event | Pregabalin |
|---|---|
| DizzinessNervous system disorders | 6/10 |
| HeadacheNervous system disorders | 2/10 |
| DiarrhoeaGastrointestinal disorders | 1/10 |
| Dry mouthGastrointestinal disorders | 1/10 |
| NauseaGastrointestinal disorders | 1/10 |
| VomitingGastrointestinal disorders | 1/10 |
| FatigueGeneral disorders | 1/10 |
| Back painMusculoskeletal and connective tissue disorders | 1/10 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/10 |
| Restless legs syndromeNervous system disorders | 1/10 |
The baseline analysis population included participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Pregabalin |
|---|---|
| Mean | 31.7 ± 4.5 |
| Sex: Female, Male(Participants) | Pregabalin |
|---|---|
| Female | 10 |
| Male | 0 |
The record gives a start of Dec 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →